Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Title
Intervention Indication Therapeutic Area Year Actions
Pembrolizumab in addition to docetaxel for chemotherapy-naive metastatic castration-resistant prostate cancer – second line Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Pembrolizumab in addition to lenvatinib for PD-L1 positive (at least 1%) non-small-cell lung cancer – first line Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Pembrolizumab in addition to platinum therapy and radiation for unresectable locally advanced head and neck squamous cell carcinoma Cisplatin (Platinol) , Pembrolizumab (Keytruda; MK-3475) Head and neck cancer Head and Neck Cancer 2019 View  |  Download
Pembrolizumab in addition to platinumpemetrexed chemotherapy for metastatic EGRF mutant non-squamous non-small-cell lung cancer – second line Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Pembrolizumab in addition to standard of care chemotherapy for extensive stage small cell lung cancer – first line Pembrolizumab (Keytruda; MK-3475) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2018 View  |  Download
Pembrolizumab in addition to trastuzumab and chemotherapy for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma – First-line Pembrolizumab (Keytruda; MK-3475) , Trastuzumab (Herceptin; RG-597) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2019 View  |  Download
Pembrolizumab in combination with Axitinib for Metastatic Renal Cell Carcinoma – first line Axitinib (Inlyta; AG-013736) , Pembrolizumab (Keytruda; MK-3475) Renal cell carcinoma (RCC) Renal Cancer 2018 View  |  Download
Pembrolizumab in Combination with Epacadostat for Unresectable or Metastatic Melanoma Epacadostat (INCB024360) , Pembrolizumab (Keytruda; MK-3475) Melanoma Skin Cancer 2018 View  |  Download
Pembrolizumab in combination with gemcitabine and cisplatin for previously untreated advanced/unresectable biliary tract cancer Cisplatin (Platinol) , Gemcitabine (Gemzar; gemcitabine hydrochloride) , Pembrolizumab (Keytruda; MK-3475) Biliary tract cancer Gastrointestinal Cancer 2021 View  |  Download
Pembrolizumab in combination with ipilimumab for advanced non-small cell lung cancer Ipilimumab (Yervoy; BMS 734016; MDX 101) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
1 2 75 76 77 78 79 113 114
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications